Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
NCT ID: NCT02290210
Last Updated: 2017-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
64 participants
INTERVENTIONAL
2014-07-24
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
NCT02557126
Study of of URC102 to Assess the Efficacy and Safety in Gout Patients
NCT04804111
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
NCT00080210
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
NCT00325195
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
NCT01082640
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo x 2weeks
placebo
URC102 0.25mg
0.25mg URC102 x 2weeks
URC102 0.25mg
URC102 0.5mg
0.5mg URC102 x 2weeks
URC102 0.5mg
URC102 1.0mg
1.0mg URC102 x 2weeks
URC102 1.0mg
URC102 2.0mg
2.0mg URC102 x 2weeks
URC102 2.0mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
URC102 0.25mg
URC102 0.5mg
URC102 1.0mg
URC102 2.0mg
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
JW Pharmaceutical
Seoul, Seocho-dong, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
URC102KR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.